The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease

Imprialos, Κonstantinos; Stavropoulos, Konstantinos; Doumas, Michael; Athyros, Vasilios G.

doi:10.1177/00033197211005597

Cited by 2 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also observed an improvement in ALT, AST, ALP, and LDH values in RAN-treated groups. Additionally, Esenboga et al reported that RAN significantly reduced ALT and AST levels in rats with coronary artery disease and non-alcoholic fatty liver disease (Esenboga et al, 2022), further supporting the potential of RAN in preventing hepatocyte damage (Han et al, 2018;Imprialos et al, 2022).…”

Section: Discussionmentioning

confidence: 92%

A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats

Polat

Sarı

Tanriverdi

et al. 2023

Preprint

View full text Add to dashboard Cite

Methotrexate (MTX) is an important drug for rheumatic and non-rheumatic disease therapy. MTX has been associated with many adverse effects ranging from asymptomatic transaminase elevation to fibrotic tissue formation and fatal hepatic necrosis due to oxidative stress. Concerns regarding potential liver toxicity have led to the avoidance of medication, termination, or advice for inquiries in clinical care. The protective and therapeutic effects of a new generation anti-angina drug, ranolazine (RAN), on MTX-induced liver damage were investigated by evaluating its antioxidant mechanism in rats. Thirty-two female Wistar Albino rats were randomly assigned to Control, RAN, prophylaxis, and treatment groups (n=8/group). Liver function enzymes, histopathological assessment and serum biochemical parameters were examined. Malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH) were also measured in liver tissue. MTX administration caused mononuclear inflammation, vascular congestion, ductal proliferation, vacuolization, and fibrosis as evaluated using Roening grading and increases in aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and lactate dehydrogenase levels ( p<0.05) in the blood, which is compatible with hepatocyte damage in the blood and increased MDA levels in the tissue. Histopathologically, vascular congestion and ductal proliferation, and biochemically, MDA and SOD levels and serum biochemical parameters, significantly decreased in the RAN+MTX and MTX+RAN groups ( p<0.001) when compared with the MTX group. No significant changes were observed in terms of SOD and GSH levels and fibrosis scores in RAN-administered groups ( p>0.05). According to our results, RAN may be a potential hepatoprotective agent against MTX-induced liver injury.

show abstract

Section: Discussionmentioning

confidence: 92%

A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats

Polat

Sarı

Tanriverdi

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury

Wei,

Zhao,

Liu

et al. 2024

Molecules

View full text Add to dashboard Cite

Liver disease is a global health problem that affects the well-being of tens of thousands of people. Dihydroquercetin (DHQ) is a flavonoid compound derived from various plants. Furthermore, DHQ has shown excellent activity in the prevention and treatment of liver injury, such as the inhibition of hepatocellular carcinoma cell proliferation after administration, the normalization of oxidative indices (like SOD, GSH) in this tissue, and the down-regulation of pro-inflammatory molecules (such as IL-6 and TNF-α). DHQ also exerts its therapeutic effects by affecting molecular pathways such as NF-κB and Nrf2. This paper discusses the latest research progress of DHQ in the treatment of various liver diseases (including viral liver injury, drug liver injury, alcoholic liver injury, non-alcoholic liver injury, fatty liver injury, and immune liver injury). It explores how to optimize the application of DHQ to improve its effectiveness in treating liver diseases, which is valuable for preparing potential therapeutic drugs for human liver diseases in conjunction with DHQ.

show abstract

The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease

Cited by 2 publications

References 13 publications

A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats

A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats

Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury

Contact Info

Product

Resources

About